GBA Biology and Therapies

DEADLINE

MAY31

The Michael J. Fox Foundation and The Silverstein Foundation for Parkinson's with GBA will award one-to-two-year grants for GBA research to advance understanding of GBA biology and accelerate therapeutic approaches.

This program seeks proposals for research studying:

How GBA mutations lead to PD

Mechanisms underlying GCase dysfunction in the absence of GBA mutations

Mutations in the glucocerebrosidase (GBA) gene are one of the most common risk factors for Parkinson's disease. GBA encodes a lysosomal enzyme, beta-glucocerebrosidase (GCase). Reduced GCase activity is associated with GBA mutations and has been reported in idiopathic PD, suggesting a more general role for GCase pathway dysfunction in Parkinson's. The exact cellular mechanism by which GCase deficits contribute to the pathogenesis of PD remains unclear, warranting further investigation.

Deadlines

Pre-Proposals Due:

Full Proposal Invitations:

Full Proposals Due (by invite only):

Anticipated Award Announcement:

Anticipated Funding:

Fall 2018

May 31, 2018 – 5 p.m. US ET

July 2018

August 20, 2018 – 5 p.m. US ET

October 2018

November 2018

FUNDING OPPORTUNITIES INFORMATIONAL WEBINAR

May 10, 2018

12 p.m. - 1 p.m. US ET

This webinar provides an overview of MJFF's funding strategy, funding opportunities, how to apply for funding and the review process.